CollPlant signed an exclusive distribution agreement with Arthrex for Vergenix™STR (soft tissue repair matrix) for the treatment of tendinopathy. As of December, Arthrex will exclusively distribute the CE Marked product in Europe, the Middle-East, India and certain African countries. The first order is expected to be supplied next month.
In 1Q16, CollPlant announced positive final clinical trial results for VergenixSTR in the treatment of tendinopathy. The objective of the prospective, open label, single arm trial was to demonstrate safety and performance of VergenixSTR in 20 patients suffering from tennis elbow. All patients were followed for six months, and performance compared very favorably to published results of standard-of-care therapies.
CollPlant signed an exclusive distribution agreement with Arthrex for Vergenix™STR (soft tissue repair matrix) for the treatment of tendinopathy. As of December, Arthrex will exclusively distribute the CE Marked product in Europe, the Middle-East, India and certain African countries. The first order is expected...
CollPlant signed an exclusive distribution agreement with Arthrex for Vergenix™STR (soft tissue repair matrix) for the treatment of tendinopathy. As of December, Arthrex will exclusively distribute the CE Marked product in Europe, the Middle-East, India and certain African countries. The first order is expected to be supplied next month.
In 1Q16, CollPlant announced positive final clinical trial results for VergenixSTR in the treatment of tendinopathy. The objective of the prospective, open label, single arm trial was to demonstrate safety and performance of VergenixSTR in 20 patients suffering from tennis elbow. All patients were followed for six months, and performance compared very favorably to published results of standard-of-care therapies.
Copy to clipboard 
